• Explore /
  • Poster
  • / Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC).

Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC).

Abstract Poster

Authors

Frede Donskov

Frede Donskov

Aarhus University Hospital, Aarhus, Denmark

Frede Donskov , Robert J. Motzer , Eric Voog , Elizabeth J. Hovey , Carsten Grüllich , Louise M. Nott , Katharine Ellen Cuff , Thierry Gil , Niels Viggo Jensen , Christine Chevreau , Sylvie Negrier , Reinhard Depenbusch , Lothar Bergmann , Izzy Cornelio , Anne Champsaur , Bernard J. Escudier , Sumanta K. Pal , Thomas Powles , Toni K. Choueiri

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT01865747

Citation

J Clin Oncol 35, 2017 (suppl; abstr 4578)

DOI

10.1200/JCO.2017.35.15_suppl.4578

Abstract #

4578

Poster Bd #

256

Abstract Disclosures

Similar Posters

First Author: Antoine Thiery-Vuillemin

First Author: Nizar M. Tannir

First Author: Ignacio Duran

First Author: Thomas Powles